Lilly(US:LLY) Xin Hua Cai Jing·2025-11-09 08:13Core Insights - Eli Lilly announced the official launch of its Shanghai Innovation Incubator (Lilly Gateway Labs, LGL) during the "2025 Lilly China Science Day" forum, marking its second incubator in China after Beijing [2] - The incubator has signed its first resident company, Molecular Heart, and established strategic partnerships with three local firms: Saintin Biotech, Insilico Medicine, and Suzhou Almai Biotechnology, aiming to accelerate the market entry of breakthrough therapies [2][3] - The Shanghai incubator is designed to accommodate 8 to 10 high-potential biotech companies and around 100 research talents, providing top-tier laboratory space and access to Eli Lilly's network of scientists and executives [3] Company Strategy - Eli Lilly's establishment of the Shanghai incubator is part of a broader strategy to enhance its external innovation framework in China, which includes venture capital, innovation cooperation centers, and incubators [2][4] - The company aims to leverage its international experience and global network to optimize the biopharmaceutical ecosystem in Shanghai, contributing to the city's goal of becoming a world-class biopharmaceutical industry cluster [3][4] - Eli Lilly has been actively collaborating with local enterprises since 2008, establishing a comprehensive external innovation matrix that spans the entire drug development cycle from target discovery to commercialization [4]